Phase II Expansion Trial Evaluating Axitinib in Patients With Unresectable Recurrent, or Metastatic Head and Neck Cancer Utilizing Choi Response Criteria Phase
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Axitinib (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Apr 2021 Status changed from active, no longer recruiting to completed.
- 20 Oct 2020 Results published in the Cancer
- 19 Jun 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.